Loading
TP
Terns Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Gengos Andrew, was filed 30 Jun 2025.
Terns Pharmaceuticals, Inc.: what insiders have been doing
Terns Pharmaceuticals, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 22 October 2026, 22 filings were filed, from 4 insiders.
All open-market trades in the period are sales: 12 sales worth €6.1M, by 3 insiders, with no purchase on record. Biggest ticket of the year: €2.3M, sold by Burroughs Amy L. and made public on 6 January 2026.
Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 22 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 35 purchases against 44 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
130
Thresholds
n/a
Buy Volume
€52M
35 ops. · all time
Sell Volume
€18M
44 ops. · all time
Who traded when
BuySaleAmy L. Burroughs3 buys8 sales
Emil Kuriakose7 sales
Andrew Gengos5 buys
Jill M. Quigley3 sales
Mark J. Vignola2 sales
Melita Sun Jung1 buy
Since the insiders bought
- -0.9%Entry 66.02 · Close at T+365 65.43
- -0.9%Entry 66.02 · Close at T+365 65.43
- -0.9%Entry 66.02 · Close at T+365 65.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-85.6M
Last declaration on 2 April 2026
Declarations130 total
942 shares@ US$52.752649.9% of flowCommon StockSEC:0001892413-26-000006:0
11,813 shares@ US$46.577.8% of flowCommon StockSEC:0001872564-26-000008:1
2,770 shares@ US$47.301.9% of flowCommon StockSEC:0001872564-26-000008:2
14,583 shares@ US$4.6415.3% of flowCommon StockSEC:0001872564-26-000008:0
2,341 shares@ US$38.071.2% of flowCommon StockSEC:0001872564-26-000006:1
8,159 shares@ US$39.224.4% of flowCommon StockSEC:0001872564-26-000006:2
4,083 shares@ US$39.802.2% of flowCommon StockSEC:0001872564-26-000006:3
14,583 shares@ US$4.6414.8% of flowCommon StockSEC:0001872564-26-000006:0
27,083 shares@ US$4.641.8% of flowCommon StockSEC:0001872564-26-000004:1
14,583 shares@ US$4.640.9% of flowCommon StockSEC:0001872564-26-000004:3
61,228 shares@ US$37.0231.7% of flowCommon StockSEC:0001872564-26-000004:4
7,521 shares@ US$37.533.9% of flowCommon StockSEC:0001872564-26-000004:5
56,250 shares0Common StockSEC:0001892413-26-000004:0
150,000 shares0Common StockSEC:0001872564-26-000004:0
68,750 shares0Common StockSEC:0001563623-26-000002:0
150,000 sharesCommon StockSEC:0001872564-26-000002:1
71,339 shares@ US$38.1037.8% of flowCommon StockSEC:0001872564-26-000002:2
955 shares@ US$38.3626.6% of flowCommon StockSEC:0001892413-26-000002:1
21,551 shares@ US$4.6422.0% of flowCommon StockSEC:0001872564-26-000002:0
200 shares@ US$39.607.8% of flowCommon StockSEC:0001892413-26-000002:0
24,520 shares@ US$18.0034.4% of flowCommon StockSEC:0001799780-25-000004:1
24,520 shares@ US$9.2460.1% of flowCommon StockSEC:0001799780-25-000004:0
944 shares@ US$7.84647.3% of flowCommon StockSEC:0001892413-25-000004:0
853 shares@ US$4.26713.6% of flowCommon StockSEC:0001562180-25-005308:0
5,000 shares@ US$3.9320.3% of flowCommon StockSEC:0001562180-25-005120:1
Canonical exit: 25 Sept 2025 (T+90)
25 of 130 declarations
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for metabolic and liver diseases. It is listed on NASDAQ under the ticker TERN.
